2. Search Result
Search Result
Results for "

reversal

" in MedChemExpress (MCE) Product Catalog:

66

Inhibitors & Agonists

1

Screening Libraries

1

Peptides

1

Inhibitory Antibodies

8

Natural
Products

3

Isotope-Labeled Compounds

1

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14946
    Amifampridine

    3,4-Diaminopyridine

    		 Potassium Channel Neurological Disease
    Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .
    Amifampridine
  • HY-114268
    BRD-K98645985
    3 Publications Verification

    		 HIV Infection
    BRD-K98645985 is a BAF (mammalian SWI/SNF) transcriptional repression inhibitor with an EC50 of ~2.37 μM. BRD-K98645985 binds ARID1A-specific BAF complexes, prevents nucleosomal positioning, and potently reverses HIV-1 latency, without T cell activation or toxicity .
    BRD-K98645985
  • HY-B0079
    Sugammadex sodium

    Org25969

    		 Drug Derivative Cardiovascular Disease Neurological Disease Cancer
    Sugammadex sodium is a synthetic γ-cyclodextrin derivative, and acts as a reversal agent for neuromuscular block. Sugammadex sodium shows nephroprotective effect in ischemia-reperfusion injury .
    Sugammadex sodium
  • HY-16689
    VU 0240551
    1 Publications Verification

    		 Potassium Channel Others
    VU 0240551 is a potent neuronal K-Cl cotransporter KCC2 inhibitor (IC50=560 nM) and is selective versus NKCC1. VU 0240551 also inhibits hERG and L-type Ca 2+ channels. VU 0240551 attenuates GABA-induced hyperpolarization of P cells, produces a positive shift in the P cell GABA reversal potential and enhances P cell synaptic transmission .
    VU 0240551
  • HY-118773
    MreB Perturbing Compound A22 hydrochloride

    A22 hydrochloride

    		 Bacterial Infection
    MreB Perturbing Compound A22 hydrochloride (A22 hydrochloride) is a reversible MreB inhibitor and antimicrobial agent that exhibits bacteriostatic activity against Escherichia coli, with low activity against Gram-positive bacteria. MreB Perturbing Compound A22 hydrochloride rapidly and reversally delocalizes MreB from the helical/circular structures in cells, impairs MreB function, and reduces the binding of MreB to the chromosomal region proximal to the replication origin. MreB Perturbing Compound A22 hydrochloride alters the cell morphology of caulobacters to round/lemon-shaped, slows caulobacter growth, blocks their cell division, and induces the formation of spherical morphology, asymmetric division, and anucleate cells in Escherichia coli. MreB Perturbing Compound A22 hydrochloride is used for studies related to bacterial rod-shaped morphology determination, chromosome segregation, and cell division mechanisms .
    MreB Perturbing Compound A22 hydrochloride
  • HY-123538
    GRK2 Inhibitor 1

    		Dopamine Receptor G Protein-coupled Receptor Kinase (GRK) Cardiovascular Disease
    GRK2 Inhibitor 1 (methyl 5-[2-(5-nitro-2-furyl)vinyl]-2-furoate) is a dual GRK2/β-ARK1 inhibitor that induces dopamine (DA) inhibition reversal (DIR). GRK2 Inhibitor 1 can also block serotonin-induced or neurotensin-induced DIR reversal. Note: DIR refers to the phenomenon in which neurons in addiction-related brain pathways become less sensitive to DA inhibition when exposed to moderate concentrations of DA for a long time .
    GRK2 Inhibitor 1
  • HY-W587796
    6-Phosphoglucono-δ-lactone

    6-PGδL; 6-Phosphonoglucono-D-lactone

    		 Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    6-Phosphoglucono-δ-lactone (6-PGδL), a reversal substrate of glucose-6-phosphate dehydrogenase (G6PD), is an intermediate compound in the oxidative branch of the pentose phosphate pathway (PPP). 6-Phosphoglucono-δ-lactone produced from D-glucose-6-phosphate by glucose-6-phosphate dehydrogenase (G6PDH) and is converted to 6-phosphoglutonate by lactonase. 6-Phosphoglucono-δ-lactone can be used for heart failure, type 2 diabetes and cancers research .
    6-Phosphoglucono-δ-lactone
  • HY-P5391
    LL-37(17-32)

    		Bacterial Others
    LL-37(17-32) is a biological active peptide. (This peptide is an active segment of LL-37, a peptide derived from the C-terminal domain of human cathelicidin antimicrobial peptide. It has been reported that the LL17-32 peptide exhibits reversal effect on ABCG2-mediated multidrug resistance in cancer cell lines.)
    LL-37(17-32)
  • HY-W035709
    Hydrocinchonine

    Dihydrocinchonine

    		 P-glycoprotein Apoptosis Cancer
    Hydrocinchonine (Dihydrocinchonine) is a multidrug resistance (MDR)-reversal agent. Hydrocinchonine directly inhibits the function and expression of P-gp, which is the mechanism by which it reverses MDR. Hydrocinchonine exerts synergistic apoptotic effect with Paclitaxel (HY-B0015) in MES-SA/DX5 cells. Hydrocinchonine can be used for the study of gynecological malignant tumors (such as uterine sarcoma) with drug resistance caused by excessive expression of P-gp .
    Hydrocinchonine
  • HY-N1514
    Ganoderenic acid B

    		P-glycoprotein Cancer
    Ganoderenic acid B is a lanostane-type triterpene isolated from Ganoderma lucidum. Ganoderenic acid B exhibits potent reversal effect on ABCB1-mediated multidrug resistance of HepG2/ADM cells to Doxorubicin .
    Ganoderenic acid B
  • HY-18660
    Ciraparantag

    PER977

    		 Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag (PER977) is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
    Ciraparantag
  • HY-108739
    Idarucizumab

    BI 655075

    		 Thrombin Cardiovascular Disease
    Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
    Idarucizumab
  • HY-149809
    AcrB-IN-1

    		Bacterial Infection
    AcrB-IN-1 (Compound H6) is a potent AcrB inhibitor. AcrB-IN-1 can be used for the reversal of bacterial multidrug resistance .
    AcrB-IN-1
  • HY-110152
    LSN2463359

    		mGluR Neurological Disease
    LSN2463359 is positive allosteric modulator of metabotropic glutamate 5 (mGlu5). LSN2463359 attenuates aspects of the behavioral response to administration of the competitive NMDA receptor antagonist. LSN2463359 selectively attenuates reversal learning deficits observed in the neurodevelopmental MAM E17 model . LSN2463359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LSN2463359
  • HY-169004
    CBT-295

    		TGF-beta/Smad Interleukin Related Neurological Disease Inflammation/Immunology
    CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy .
    CBT-295
  • HY-B0079A
    Sugammadex

    Org25969 free acid

    		 Drug Derivative Cardiovascular Disease Neurological Disease Cancer
    Sugammadex is a synthetic γ-cyclodextrin derivative, and acts as a reversal agent for neuromuscular block. Sugammadex shows nephroprotective effect in ischemia-reperfusion injury .
    Sugammadex
  • HY-153835
    Pegnivacogin

    		Factor Xa Others
    Pegnivacogin is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen.
    Pegnivacogin
  • HY-175838
    P-gp-IN-32

    		P-glycoprotein Cancer
    P-gp-IN-32 is a P-glycoprotein (P-gp) inhibitor. P-gp-IN-32 exhibits low cytotoxicity and potent multidrug resistance (MDR) reversal activity against Doxorubicin (HY-15142A) in MCF7/ADR cells (IC50 = 0.11 μM, reversal fold (RF) = 215.9). P-gp-IN-32 can bind to P-gp directly, induce a conformation change of P-gp and inhibit the efflux function. P-gp-IN-32 can be used for the research of cancer, such as breast cancer .
    P-gp-IN-32
  • HY-101337A
    Imiloxan hydrochloride

    RS 21361

    		 Adrenergic Receptor Metabolic Disease
    Imiloxan (RS 21361) hydrochloride is a potent and selective alpha 2B-adrenoceptor antagonist. Imiloxan hydrochloride produces a dose-related reversal of Guanoxabenz (HY-U00123)-induced maximal mydriasis in male rats. Imiloxan hydrochloride has the potential for acute kidney injury research .
    Imiloxan hydrochloride
  • HY-123744
    PD-156707

    		Endothelin Receptor Cardiovascular Disease Neurological Disease
    PD-156707 is an orally active, nonpeptide and selective Endothelin-A receptor antagonist. PD-156707 binds to human ET-A and ET-B receptors with Ki values of 0.17 nM and 133.8 nM, respectively. PD-156707 shows reversal of established chronic hypoxic pulmonary hypertension in rats. PD-156707 can be used for the study of diseases associated with abnormal ET-A receptor activation, particularly pulmonary hypertension, stroke, and heart failure .
    PD-156707
  • HY-144366
    P-gp inhibitor 3

    		P-glycoprotein Cancer
    P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel .
    P-gp inhibitor 3
  • HY-177691
    CCI17464

    		Prostaglandin Receptor Neurological Disease Inflammation/Immunology
    CCI17464 is a selective, orally active EP4 partial agonist with a pKi of 7.1. CCI17464 can be used in a Freund's complete adjuvant (FCA) acute rat inflammatory pain model and shows complete reversal of allergic reactions .
    CCI17464
  • HY-123384
    KR30031

    		P-glycoprotein Cardiovascular Disease Cancer
    KR30031, a Verapamil (HY-14275) analog, is an orally active P-glycoprotein (P-gp) inhibitor. KR30031 enhances the cytotoxicity of anticancer agents by inhibiting P-gp with fewer cardiovascular adverse effects. KR30031 can be used to study multidrug resistance (MDR) reversal in cancer .
    KR30031
  • HY-14946A
    Amifampridine phosphate

    3,4-Diaminopyridine phosphate

    		 Potassium Channel Neurological Disease
    Amifampridine (3,4-Diaminopyridine) phosphate is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB). Amifampridine phosphate is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine phosphate increases transmitter release from neuromuscular junctions (NMJs). Amifampridine phosphate can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .
    Amifampridine phosphate
  • HY-W035709R
    Hydrocinchonine (Standard)

    Dihydrocinchonine (Standard)

    		 Reference Standards P-glycoprotein Apoptosis Cancer
    Hydrocinchonine (Dihydrocinchonine) (Standard) is the analytical standard of Hydrocinchonine (HY-W035709). This product is used for research and analytical purposes.Hydrocinchonine is a multidrug resistance (MDR)-reversal agent. Hydrocinchonine directly inhibits the function and expression of P-gp, which is the mechanism by which it reverses MDR. Hydrocinchonine exerts synergistic apoptotic effect with Paclitaxel (HY-B0015) in MES-SA/DX5 cells. Hydrocinchonine can be used for the study of gynecological malignant tumors (such as uterine sarcoma) with drug resistance caused by excessive expression of P-gp .
    Hydrocinchonine (Standard)
  • HY-178466
    Tubulin polymerization/P-gp-IN-1

    		Microtubule/Tubulin P-glycoprotein Apoptosis Cancer
    Tubulin polymerization/P-gp-IN-1 is a Tubulin polymerization/P-gp dual inhibitor. Tubulin polymerization/P-gp-IN-1 inhibits tubulin polymerization and induces G2/M arrest and apoptosis. Tubulin polymerization/P-gp-IN-1 reverses MDR by inhibiting P-gp efflux function. Tubulin polymerization/P-gp-IN-1 has dual functions: direct antitumor activity and reversal of P-gp-mediated Cisplatin (HY-17394) resistance. Tubulin polymerization/P-gp-IN-1 stable binds to the tubulin CBS (ΔG = −12.4 kcal/mol) and the P-gp hydrophobic lumen (ΔG = −10.8 kcal/mol). Tubulin polymerization/P-gp-IN-1 can be used for the study of drug-resistant cervical cancer .
    Tubulin polymerization/P-gp-IN-1
  • HY-159818
    Amogammadex

    		Drug Derivative Others
    Amogammadex is a reversal agent for rocuronium and vecuronium .
    Amogammadex
  • HY-153835A
    Pegnivacogin sodium

    		Factor Xa Others
    Pegnivacogin sodium is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen.
    Pegnivacogin sodium
  • HY-161645
    P-gp modulator-4

    		P-glycoprotein Cancer
    P-gp modulator-4 (compound 4c) inhibits the efflux function of P-glycoprotein (P-gp). P-gp modulator-4 shows multidrug resistance (MDR) in cancer reversal activity (IC50 of Paclitaxel (HY-B0015) = 8.80, reversal fold = 211.8) .
    P-gp modulator-4
  • HY-109796
    NIK250

    		Bacterial Infection
    NIK250 is a potent multiple drug resistance (MDR) reversal agent that inhibits P-glycoprotein .
    NIK250
  • HY-106753
    Tolnapersine

    		P-glycoprotein Others
    Tolnapersine exhibits multidrug resistance (MDR) reversal activity, which reverses the resistance of tumor cells to multiple chemotherapy drugs by affecting P-glycoprotein (Pgp) on the cell membrane .
    Tolnapersine
  • HY-149360
    P-gb-IN-1

    		P-glycoprotein Cancer
    P-gb-IN-1 (compound Ⅲ-8), a 2,5-disubstituted furan derivative, is a highly effective, broadspectrum P-glycoprotein (P-gp) inhibitor. P-gb-IN-1 displayed the reversal activity by inhibiting P-gp efflux. P-gb-IN-1 has a potent affinity to P-gp by forming H-bond interactions with residues Asn 721 and Met 986. P-gb-IN-1 possesses broad-spectrum reversal activity and low toxicity in MCF-7/ADR cells .
    P-gb-IN-1
  • HY-122445
    Resorcinolnaphthalein
    2 Publications Verification

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Inflammation/Immunology
    Resorcinolnaphthalein is a specific angiotensin-converting enzyme 2 (ACE2) enhancer and activates ACE2 activity with an EC50 value of 19.5 μM. Resorcinolnaphthalein can be used for the investigation of hypertension and renal fibrosis .
    Resorcinolnaphthalein
  • HY-116529
    Lamellarin E

    		Others Others
    Lamellarin E is a biologically active marine alkaloid, while the Lamellarin series of alkaloids show potential cytotoxicity, topoisomerase I inhibition, protein kinase inhibition, multidrug resistance reversal, and anti-HIV-1 activity .
    Lamellarin E
  • HY-18660B
    Ciraparantag acetate

    PER977 acetate

    		 Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag (PER977) acetate is a thrombin and factor Xa inhibitor. Ciraparantag acetate is a broad-spectrum reversal agent for anticoagulants, including low molecular weight heparins, unfractionated heparins, and some direct oral anticoagulants, but not VKAs .
    Ciraparantag acetate
  • HY-153836
    Anivamersen

    		Factor Xa Others
    Anivamersen is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
    Anivamersen
  • HY-153836A
    Anivamersen sodium

    		Factor Xa Others
    Anivamersen sodium is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
    Anivamersen sodium
  • HY-N12101
    Anti-inflammatory agent 57

    		Others Inflammation/Immunology
    Anti-inflammatory agent 57 (Compound 13), pyranocoumarin, is a nature product. Anti-inflammatory agent 57 can be isolated from the roots of Peucedanum praeruptorum. Anti-inflammatory agent 57 has multidrug-resistance (MDR) reversal and anti-inflammatory effect .
    Anti-inflammatory agent 57
  • HY-162369
    PID-9

    		P-glycoprotein Cancer
    PID-9 is a P-glycoprotein inhibitor. PID-9 has multidrug resistance (MDR) reversal activity (IC50 = 0.1338 μM) and low toxicity. PID-9 inhibits the transport function of P-gp without downregulating P-gp expression .
    PID-9
  • HY-118706
    PD 118440

    		Dopamine Receptor Neurological Disease
    PD 118440 is an orally active dopamine (DA) agonist. PD 118440 has significant central nervous system effects, including inhibition of striatal DA synthesis, suppression of DA neuron firing, and reversal of Reserpine (HY-N0480)-induced depression in rats .
    PD 118440
  • HY-163666
    HIV-1 inhibitor-68

    		HIV PKC Infection
    HIV-1 inhibitor-68 (compound 26) is a protein kinase C (PKC) activator derivative with reversal activity in HIV-1 latency. HIV-1 inhibitor-68 may be able to eliminate cells latently infected with HIV-1, .
    HIV-1 inhibitor-68
  • HY-101337
    Imiloxan

    RS 21361 free base

    		 Adrenergic Receptor Inflammation/Immunology
    Imiloxan (RS 21361) is a potent and selective alpha 2B-adrenoceptor antagonist. Imiloxan produces a dose-related reversal of Guanoxabenz (HY-U00123)-induced maximal mydriasis in male rats. Imiloxan has the potential for acute kidney injury research .
    Imiloxan
  • HY-18660A
    Ciraparantag TFA

    PER977 TFA

    		 Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag (PER977) TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
    Ciraparantag TFA
  • HY-149053
    OY-101

    		P-glycoprotein Cancer
    OY-101 is an orally active, potent and specific P-glycoprotein (P-gp) inhibitor. OY-101 can sensitize drug-resistant tumors and effectively reverse tumor multidrug resistance. OY-101 is improvements in water-solubility, cytotoxicity, and reversal activity compared to Tetrandrine (HY-13764) .
    OY-101
  • HY-159085
    P-gp inhibitor 24

    		P-glycoprotein Cancer
    P-gp inhibitor 24 (Compound 10) is an inhibitor for P-glycoprotein (P-gp)), that inhibits the P-gp mediated fluorescent dye efflux. P-gp inhibitor 24 exhibits multidrug resistance (MDR) reversal effect, enhances the cytotoxicity of Vincristine (HY-N0488) and Etoposide (HY-13629) in cancer cells .
    P-gp inhibitor 24
  • HY-121247
    Bromotetrandrine

    5-Bromotetrandrine; BrTet; W198

    		 P-glycoprotein Drug Derivative Cancer
    Bromotetrandrine is a potent inhibitor of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). Bromotetrandrine shows significant MDR reversal activity in vitro and in vivo, which may be related to the inhibition of P-gp overexpression and the increase in intracellular accumulation of anticancer agents. Bromotetrandrine is a brominated derivative of tetrandrine, which is promising for MDR modulator for tumor assessment .
    Bromotetrandrine
  • HY-144393
    P-gp/BCRP-IN-1

    		BCRP Cancer
    P-gp/BCRP-IN-1 (compound 19) is a potential, relatively safe, orally active and efficient efflux transporter (P-gp and BCRP) inhibitor. P-gp/BCRP-IN-1 exerts resistance reversal by inhibiting the efflux function of P-gp and BCRP. P-gp/BCRP-IN-1 can overcome the resistance and improve the oral bioavailability of PTX (Paclitaxel) .
    P-gp/BCRP-IN-1
  • HY-18660S
    Ciraparantag-d8 (tetra(hydrochloride) diacetate)

    PER977-d8 tetrahydrochloride diacetate

    		 Isotope-Labeled Compounds Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag-d8 (PER977-d8) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
    Ciraparantag-d8 (tetra(hydrochloride) diacetate)
  • HY-180988
    Heparin reversal agent-1

    		Biochemical Assay Reagents Cardiovascular Disease
    Heparin reversal agent-1 (Compound QA-1) is a reversal agent for Heparin (HY-17567). Heparin reversal agent-1 shows neutralization activity. Heparin reversal agent-1 completely reverses the anticoagulant activity of both unfractionated heparin and low-molecular-weight heparins, including Dalte, Enoxa, and Nadro .
    Heparin reversal agent-1
  • HY-14946R
    Amifampridine (Standard)

    3,4-Diaminopyridine (Standard)

    		 Reference Standards Potassium Channel Neurological Disease
    Amifampridine (Standard) is the analytical standard of Amifampridine. This product is intended for research and analytical applications. Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research .
    Amifampridine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: